Hjem › Non-Hodgkins lymfom › Tennessee
Kliniske studier for Non-Hodgkins lymfom i Tennessee
24 studier for Non-Hodgkins lymfom søker deltakere på steder i Tennessee.
Byer i Tennessee
Offisiell studietekst (engelsk)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05006716Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
- Vanderbilt University/Ingram Cancer Center, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07763210A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- SCRI Oncology Partners ( Site 0100), Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07519772TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
RekruttererFase 2
Alder 12 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT02693535A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- SCRI Oncology Partners, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07101328A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07226843A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT07195916Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06526793Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Tennessee Oncology, Chattanooga
- Tennessee Oncology, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06806033TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- SCRI Oncology Partners, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07082803A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Research Site, Franklin
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07123454Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT05826535Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04851119A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Sarah Cannon Research Institute SCRI, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- SCRI Oncology Partners, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- St. Jude Childrens Research Hospital, Memphis
- Vanderbilt University, Nashville
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545Familial Investigations of Childhood Cancer Predisposition
- St. Jude Children's Research Hospital, Memphis
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 17. jun. 2026 · NCT03050268Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
- Baptist Memorial Hospital for Women, Memphis
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06418204A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Tennessee Oncology, Nashville
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT06876662SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- SCRI Oncology Partners, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2025 · NCT06119685Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.